Emergency Medicine
Current evidence for COVID-19 therapies: a systematic literature review
19 Mar, 2021 | 08:36h | UTC
How do you treat coronavirus? Here are physicians’ best strategies
19 Mar, 2021 | 08:33h | UTCHow do you treat coronavirus? Here are physicians’ best strategies – Science (a few articles per month are free)
Video: Coronavirus Update with Carlos del Rio and Preeti Malani
19 Mar, 2021 | 08:24h | UTCCoronavirus Update With Carlos del Rio and Preeti Malani – JAMA
Review: Diagnosis and Management of Transient Ischemic Attack and Acute Ischemic Stroke
18 Mar, 2021 | 08:54h | UTCDiagnosis and Management of Transient Ischemic Attack and Acute Ischemic Stroke: A Review – JAMA
Systematic Review: Thoracic imaging tests for the diagnosis of COVID‐19
18 Mar, 2021 | 09:05h | UTCThoracic imaging tests for the diagnosis of COVID‐19 – Cochrane Library
Consensus Document: Management of acute myocarditis and chronic inflammatory cardiomyopathy
17 Mar, 2021 | 02:28h | UTC
A randomized, noninferiority, controlled trial of two doses of intravenous subdissociative ketamine for analgesia in the emergency department
17 Mar, 2021 | 02:13h | UTCA randomized, noninferiority, controlled trial of two doses of intravenous subdissociative ketamine for analgesia in the emergency department – Academic Emergency Medicine (link to abstract – $ for full-text)
Commentaries: Lower dose of ketamine is as effective as the standard dose to treat pain in adults – Loyola University Health System AND Lower doses of ketamine shown to be non-inferior for acute pain control in the emergency setting – 2 Minute Medicine
FDA: Why you should not use Ivermectin to treat or prevent COVID-19
17 Mar, 2021 | 02:51h | UTCWhy You Should Not Use Ivermectin to Treat or Prevent COVID-19 – U.S. Food & Drug Administration
Commentary: FDA Rejects Ivermectin, Despite Growing Interest In Some Corners Of The Internet – Brief19
Related: RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19
COVID‐19 and its cardiovascular effects: a systematic review of prevalence studies
17 Mar, 2021 | 02:52h | UTC
Commentary on Twitter
How common are pre‐existing heart & blood vessel problems in #COVID19? What are most common complications affecting heart & blood vessels in #COVID19? @CochraneHeart review of prevalence studies: https://t.co/rDqz2GyrpH
— The Cochrane Library (@CochraneLibrary) March 12, 2021
COVID antibody treatments show promise for preventing severe disease
17 Mar, 2021 | 02:46h | UTCCOVID antibody treatments show promise for preventing severe disease – Nature
B.1.1.7 variant linked to 55% higher mortality compared to other strains of SARS-CoV-2
16 Mar, 2021 | 02:32h | UTCOriginal study: Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 – Nature
Related: Death rate 64% higher with B117 COVID variant, study finds (study and commentary)
Commentary on Twitter (thread – Click for more)
https://mobile.twitter.com/_nickdavies/status/1371441682089132032
The oxygen cascade during exercise in health and disease
16 Mar, 2021 | 01:28h | UTCThe Oxygen Cascade During Exercise in Health and Disease – Mayo Clinic Proceedings
Revisiting the Ten Commandments of Emergency Medicine: A Resident’s Perspective
14 Mar, 2021 | 20:26h | UTCRevisiting the Ten Commandments of Emergency Medicine: A Resident’s Perspective – Annals of Emergency Medicine (free for a limited period)
Commentary: Ten Commandments of Emergency Medicine Revisited – Journal Feed
New COVID-19 risk calculator can predict severe disease or death among hospitalized patients with COVID-19
14 Mar, 2021 | 20:54h | UTCSee calculator: Severe COVID-19 Adaptive Risk Predictor (SCARP)
[Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19
14 Mar, 2021 | 20:59h | UTCTherapeutic Anticoagulation in Critically Ill Patients with Covid-19-Preliminary Report – medRxiv
Related (results on moderately ill patients): [Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials
Study: Healthcare settings did not increase the risk for Covid-19 infection among health care workers in the US. Exposure outside the workplace was the strongest risk factor for SARSCoV2 seropositivity
14 Mar, 2021 | 20:41h | UTCCommentaries: Healthcare settings do not increase risk for Covid-19 infection spread – University of Maryland School of Medicine AND Did Healthcare Workers Catch Covid In Or Outside The Hospital? – MedicalResearch.com AND Community Covid-19 Risk Higher Than Workplace Risk for Health Care Personnel – Physician’s Weekly
Commentary on Twitter
Cross-sectional study finds #COVID19 exposure outside the workplace was the strongest risk factor for #SARSCoV2 seropositivity. No workplace factors were associated with seropositivity. @EmoryMedicine @UMMC @HopkinsMedicine @CDCgov https://t.co/DbdSxTEb8n
— JAMA Network Open (@JAMANetworkOpen) March 10, 2021
Consensus Statement: Preoperative management of endocrine, hormonal, and urologic medications
11 Mar, 2021 | 08:04h | UTC
AHA Scientific Statement | Opioid-Associated Out-of-Hospital Cardiac Arrest: Distinctive Clinical Features and Implications for Health Care and Public Responses
11 Mar, 2021 | 08:07h | UTC
ERS Guideline: Management of hospitalized adults with COVID-19
12 Mar, 2021 | 08:36h | UTC
COVID-19 and liver disease: mechanistic and clinical perspectives
12 Mar, 2021 | 08:29h | UTC
Update to living systematic review on covid-19 in pregnancy
12 Mar, 2021 | 08:28h | UTCNews release: Update to living systematic review on covid-19 in pregnancy – The BMJ
[Press release – not published yet] Monoclonal antibodies reduced hospitalizations and death in Phase 3 trial for early COVID-19
11 Mar, 2021 | 08:41h | UTCPress release: Lilly’s bamlanivimab and etesevimab together reduced hospitalizations and death in Phase 3 trial for early COVID-19
Commentary: Eli Lilly’s combo therapy for COVID-19 cuts serious illness and death in large study – Reuters
Death rate 64% higher with B117 COVID variant, study finds
11 Mar, 2021 | 08:38h | UTCDeath rate 64% higher with B117 COVID variant, study finds – CIDRAP
News release: Variant B.1.1.7 of COVID-19 associated with a significantly higher mortality rate, research shows – University of Bristol
Original Study: Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study – The BMJ
[Preprint] RECOVERY trial: Convalescent plasma does not improve outcomes in patients admitted to hospital with COVID-19
11 Mar, 2021 | 08:43h | UTC
Commentary on Twitter (thread – click for more)
RECOVERY Pre-print:
Convalescent plasma does not improve survival in patients hospitalised with COVID-19 in this randomised controlled trial involving 11,558 patients:https://t.co/36YZwJNY3Q pic.twitter.com/sKR095n1PC
— Martin Landray (@MartinLandray) March 10, 2021
State of the Art Review | Severe covid-19 pneumonia: pathogenesis and clinical management
11 Mar, 2021 | 08:37h | UTCSevere covid-19 pneumonia: pathogenesis and clinical management – The BMJ